Cargando…

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Fiore, F Di, Charbonnier, F, Lefebure, B, Laurent, M, Pessot, F Le, Michel, P, Frebourg, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527802/ https://www.ncbi.nlm.nih.gov/pubmed/18594536 http://dx.doi.org/10.1038/sj.bjc.6604451

Ejemplares similares

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
por: Di Fiore, F, et al.
Publicado: (2010)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
por: Ohishi, Tomokazu, et al.
Publicado: (2020)

Genetic variations of the A13/A14 repeat located within the EGFR 3′ untranslated region have no oncogenic effect in patients with colorectal cancer
por: Sarafan-Vasseur, Nasrin, et al.
Publicado: (2013)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
por: Ye, Hua, et al.
Publicado: (2020)

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017)

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
por: Kishiki, Tomokazu, et al.
Publicado: (2014)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience
por: Blons, Hélène, et al.
Publicado: (2013)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
por: Cafiero, Concetta, et al.
Publicado: (2020)

Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
por: GUTIÉRREZ, CRISTINA, et al.
Publicado: (2013)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Tougeron, D, et al.
Publicado: (2014)

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
por: Feigelson, Heather Spencer, et al.
Publicado: (2012)

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition
por: Rouleau, E, et al.
Publicado: (2008)

Regulatory T Lymphocytes Are Associated with Less Aggressive Histologic Features in Microsatellite-Unstable Colorectal Cancers
por: Tougeron, David, et al.
Publicado: (2013)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
por: Zocche, David M., et al.
Publicado: (2015)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan
por: Awidi, Muhammad, et al.
Publicado: (2019)

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2018)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
por: Hsieh, Meng-Chiao, et al.
Publicado: (2018)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j9o40sjlo18fmeql0va250s6fb